The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

Resistance to current therapies still impacts a significant number of melanoma patients and can be regulated by epigenetic alterations. Analysis of global cytosine methylation in a cohort of primary melanomas revealed a pattern of early demethylation associated with overexpression of oncogenic transcripts. Loss of methylation and associated overexpression of the CSF 1 receptor (CSF1R) was seen in a majority of tumors and was driven by an alternative, endogenous viral promoter in a subset of samples. CSF1R was particularly elevated in melanomas with BRAF and other MAPK activating mutations. Furthermore, rebound ERK activation after BRAF inhibition was associated with RUNX1-mediated further upregulation of CSF-1R and its ligand IL-34. Importantly, increased CSF-1R and IL-34 overexpression were detected in an independent cohort of resistant melanomas. Inhibition of CSF-1R kinase or decreased CSF-1R expression by RNAi reduced 3-D growth and invasiveness of melanoma cells. Coinhibition of CSF-1R and BRAF resulted in synergistic efficacy in vivo. To our knowledge, our data unveil a previously unknown role for the autocrine-regulated CSF-1R in BRAF V600E resistance and provide a preclinical rationale for targeting this pathway in melanoma.

[1]  J. Taube,et al.  Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas , 2017, Melanoma research.

[2]  H. Ishwaran,et al.  Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.

[3]  Wira Eka Putra,et al.  Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. , 2016, Cancer research.

[4]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[5]  D. Schadendorf,et al.  Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). , 2016 .

[6]  Deborah S. Barkauskas,et al.  Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma , 2016, Oncoimmunology.

[7]  A. Ribas,et al.  Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy , 2016, Therapeutic advances in medical oncology.

[8]  M. Ringnér,et al.  DNA methylation subgroups in melanoma are associated with proliferative and immunological processes , 2015, BMC Medical Genomics.

[9]  Antoni Ribas,et al.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance , 2015, Cell.

[10]  M. van de Rijn,et al.  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.

[11]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[12]  T. Graeber,et al.  Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition , 2015, BMC Cancer.

[13]  L. Chin,et al.  Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. , 2015, The Journal of clinical investigation.

[14]  J. Massagué,et al.  Therapy-induced tumour secretomes promote resistance and tumour progression , 2015, Nature.

[15]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[16]  E. Oancea,et al.  Genome-wide transcriptome analysis of human epidermal melanocytes. , 2014, Genomics.

[17]  P. De Baetselier,et al.  Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression , 2014, Front. Immunol..

[18]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[19]  S. H. van der Burg,et al.  Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy , 2014, PloS one.

[20]  C. Lian,et al.  Melanoma epigenetics: novel mechanisms, markers, and medicines , 2014, Laboratory Investigation.

[21]  E. Stanley,et al.  CSF-1 receptor signaling in myeloid cells. , 2014, Cold Spring Harbor perspectives in biology.

[22]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[23]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[24]  Antoni Ribas,et al.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.

[25]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[26]  Gavin D. Meredith,et al.  Genome-wide methylated CpG island profiles of melanoma cells reveal a melanoma coregulation network , 2013, Scientific Reports.

[27]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[28]  N. Ifrah,et al.  IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ , 2013, PloS one.

[29]  James A. Fagin,et al.  Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression , 2013, PloS one.

[30]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[31]  M. Mehler,et al.  The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. , 2012, Developmental biology.

[32]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[33]  M. Herlyn,et al.  Melanoma‐derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature , 2012, Pigment cell & melanoma research.

[34]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[35]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[36]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[37]  J. Kriegsmann,et al.  Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. , 2012, Cancer research.

[38]  D. Krag,et al.  GRB7 is required for triple-negative breast cancer cell invasion and survival , 2012, Breast Cancer Research and Treatment.

[39]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[40]  Reid F. Thompson,et al.  Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis , 2011, PLoS genetics.

[41]  N. Rosen,et al.  Mutant BRAF melanomas--dependence and resistance. , 2011, Cancer cell.

[42]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[43]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[44]  J. Greally,et al.  DNA methylation profiling using HpaII tiny fragment enrichment by ligation-mediated PCR (HELP). , 2010, Methods.

[45]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[46]  L. Williams,et al.  Functional overlap but differential expression of CSF‐1 and IL‐34 in their CSF‐1 receptor‐mediated regulation of myeloid cells , 2010, Journal of leukocyte biology.

[47]  Ralph Stadhouders,et al.  Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma , 2010, Nature Medicine.

[48]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[49]  A. Melnick,et al.  HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. , 2010, Methods in molecular biology.

[50]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[51]  Jing Chen,et al.  CSF‐1 receptor structure/function in MacCsf1r–/– macrophages: regulation of proliferation, differentiation, and morphology , 2008, Journal of leukocyte biology.

[52]  L. Williams,et al.  Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome , 2008, Science.

[53]  Quan Chen,et al.  An analytical pipeline for genomic representations used for cytosine methylation studies , 2008, Bioinform..

[54]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[55]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[56]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[57]  Kenny Q. Ye,et al.  Comparative isoschizomer profiling of cytosine methylation: the HELP assay. , 2006, Genome research.

[58]  Frank Lyko,et al.  LUMA (LUminometric Methylation Assay)--a high throughput method to the analysis of genomic DNA methylation. , 2006, Experimental cell research.

[59]  F. Pixley,et al.  CSF-1 regulation of the wandering macrophage: complexity in action. , 2004, Trends in cell biology.

[60]  Owen J. Marshall.  PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR , 2004, Bioinform..

[61]  Wyeth W. Wasserman,et al.  ConSite: web-based prediction of regulatory elements using cross-species comparison , 2004, Nucleic Acids Res..

[62]  S. Horvath,et al.  Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Hamilton.  CSF‐1 signal transduction , 1997, Journal of leukocyte biology.

[64]  P. Jones,et al.  Altered DNA methylation and genome instability: a new pathway to cancer? , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[65]  D. Tenen,et al.  CCAAT Enhancer-Binding Protein ( C / EBP ) and AML 1 ( CBF a 2 ) Synergistically Activate the Macrophage Colony-Stimulating Factor Receptor Promoter , 1995 .

[66]  S. Leibovitch,et al.  Colony-stimulating factor 1 (CSF-1) is involved in an autocrine growth control of rat myogenic cells. , 1995, Experimental cell research.

[67]  F. Beuvon,et al.  M‐CSF (monocyte colony stimulating factor) and M‐CSF receptor expression by breast tumour cells: M‐CSF mediated recruitment of tumour infiltrating monocytes? , 1992, Journal of cellular biochemistry.

[68]  E. Bröcker,et al.  Inflammatory cell infiltrates in human melanoma at different stages of tumor progression , 1988, International journal of cancer.